Mometasone furoate in the management of asthma: A review

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1201-1208

  Tan, Ricardo A ^a   Corren, Jonathan ^b  

^a California Allergy and Asthma Medical Group   (United States)

^b Allergy Research Foundation   (United States)

Author keywords

Asthma; Inhaled steroids; Mometasone furoate; Once daily dosing; Stepwise approach

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; PREDNISONE;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL SUPPRESSION; ASTHMA; BONE DENSITY; CATARACT; CHILD GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EVENING DOSAGE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GLAUCOMA; GROWTH RATE; HUMAN; MAINTENANCE THERAPY; METERED DOSE INHALER; MORNING DOSAGE; MOUTHWASH; PEAK EXPIRATORY FLOW; POWDER INHALER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE; THRUSH;

EID: 61549083455     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Affrime MB, Kosoglou T, Thonoor CM, et al. 2000. Mometasone faroate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest, 118:1538-46.
2. Affrime MB, Kosoglou T. 2001. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate asthma [abstract]. J Allergy Clin Immunol, 107:S104.
3. Agertoft L, Pedersen S. 2000. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med, 343:1064-9.
4. Bensch GW, Prenner B, Berkowitz R, et al. 2006. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol, 96:533-40.
5. Berger WE, Milgrom H, Chervinsky P, et al. 2006. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol, 97:672-80.
6. Bousquet J, D'Urzo A, Hebert J, et al. 2000. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J, 16:808-16.
7. Chervinsky P, Nelson HS, Bernstein DI, et al. 2002. Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. Int J Clin Pract, 56:419-25.
8. Chrousos GP, Ghaly L, Shedden A, et al. 2005. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest, 128:70-7.
9. Corren J, Berkowitz R, Murray JJ, et al. 2003. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract, 57:567-72.
10. Crim C, Pierre LN, Daley-Yates PT. 2001. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther, 23:1339-54.
11. Derendorf H, Daley-Yates PT, Pierre LN, et al. 2002. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol, 42:383-7.
12. D'Urzo A, Karpel JP, Busse WW, et al. 2005. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin, 21:1281-9.
13. Fardon TC, Lee DK, Haggart K, et al. 2004. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med, 170:960-6.
14. Fish JE, Karpel JP, Craig TJ, et al. 2000. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol, 106:852-60.
15. Gulliver T, Morton R, Eid N. 2007. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs, 9:185-94.
16. Harnest U, Price D, Howes T, et al. 2008. Comparison of mometasone faroate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. Asthma, 45:215-20.
17. Karpel JP, Busse WW, Noonan MJ, et al. 2005. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother, 39:1977-83.
18. Karpel JP, Nayak A, Lumry W, et al. 2007. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir Med, 101:628-37.
19. Karpel JP, Nelson H. 2007. Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma. Curr Med Res Opin, 23:2897-911.
20. Kemp JP, Berkowitz RB, Miller SD, et al. 2000. Mometasone furoate admmistered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol, 106:485-92.
21. Lemanske R. Lockey R, Murphy K. 2004. Effects of one year of treatment with mometasone faroate metered dose inhaler (MF-MDI) on growth in children with asthma. Eur Respir J, 24:378s.
22. Meltzer EO, Wenzel S. 2006. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. J Asthma, 43:765-72.
23. Mortimer KJ, Harrison TW, Tattersfield AE. 2005. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol, 94:15-21.
24. Nathan RA, Nayak AS, Graft DF. 2001. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol, 86:203-10.
25. National Heart, Lung and Blood Institute. 2007. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007.
26. Nayak AS, Banov C, Corren J, et al. 2000. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol, 84:417-24
27. Noonan M, Karpel JP, Bensch GW, et al. 2001. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol, 86:36-43.
28. O'Connor B, Bonnaud G, Haahtela T, et al. 2001. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol, 86:397-404.
29. Sahasranaman S, Issar M, Hochhaus G. 2006. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos, 34:225-33.
30. Schinier J, Leidy NK, Gower R. 2003. Reduction in oral corticosteroid use with mometasone faroate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma, 40:383-93.
31. Skoner D, Dunn M, Lee T. 2003. Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pitiuitary-adrenal axis function in children with asthma. Am J Respir Crit Care Med, 167:A272.
32. Tayab ZR, Fardon TC, Lee DK, et al. 2007. Pharmacokinetic/ pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol, 64:698-705.
33. Teng XW, Cutler DJ, Davies NM. 2003. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos, 24:321-33.
34. Valotis A, Högger P. 2004. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res, 5:7.
35. Valotis A, Neukam K, Elert O, Högger P. 2004. Human receptor kinetics, tissue binding affinity, and stability of mometasone faroate. J Pharm Sci, 93:1337-50.
36. Wardlaw A, Larivee P, Eller J, et al. 2004. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol, 93:49-55.